Eric Faulkner, Senior Director of US Market Access and Reimbursement, will provide a luncheon keynote at the Canadian Institute’s Drug Pricing and Reimbursement in Canada conference June 24-25, 2008 in Toronto. The lecture will focus on investment and diversification strategies for augmenting the traditional pharmaceutical pipeline with emerging health technologies in response to the changing pharmaceutical landscape. The abstract for the session is as follows:
Pharmaceutical development is currently at a critical crossroads. As many blockbuster drugs go generic, innovation becomes more daunting and elusive, and emerging treatments continue to raise the bar for affordability (despite their promise), payers and other health decision makers are at the same time moving towards increasingly restrictive reimbursement and pricing policies to better balance quality and cost. What options do manufacturers have for augmenting the pipeline in the face of significant uncertainty? This session will explore the opportunities and challenges associated with key emerging technologies, including new biologics, personalized medicine, gene therapies, cellular therapies and drug/device combination strategies, and evaluate how they may fit into the health care landscape and which are poised to succeed.
Mr. Faulkner’s responsibilities at RTI Health Solutions involve evaluation of US and international pricing and reimbursement issues, health technology assessment practices, product reimbursement and commercialization strategies and changing health policy. He has recently served as an expert advisor to the Personalized Medicine Subcommittee of the President’s Council of Advisors on Science and Technology and serves on the Leadership Committee of the Health Technology Assessment for Emerging Technologies Working Group of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).
In addition to his role at RTI Health Solutions, Mr. Faulkner also serves as Director of the Genomic Biotech Institute (GBI) of the National Association of Managed Care Physicians (NAMCP) and is Editor-in-Chief of the GBI special section of the Journal of Managed Care Medicine, Genomics and Biotechnology.
Additional information about the conference is available here.
directly if you plan to attend the conference and would like to pre-arrange a meeting time with him.